• Valeriya I. Ni
  • Alexandr O. Ivantsov
  • Mariya A. Kotkova
  • Sofia V. Baskina
  • Elena V. Ponomareva
  • Rashida V. Orlova
  • Eldar E. Topuzov
  • Kirill K. Kryukov
  • Kseniya V. Shelekhova
  • Svetlana N. Aleksakhina
  • Anna P. Sokolenko
  • Evgeny N. Imyanitov

A recent study suggested a role of CHEK2 loss-of-function germ-line pathogenic variants in the predisposition to testicular cancer (TC) (AlDubayan et al. JAMA Oncol 5:514–522, 2019). We attempted to validate this finding relying on the high population frequency of recurrent CHEK2 pathogenic variants in Slavic populations. CHEK2 pathogenic alleles (c.1100delC (p.Thr367Metfs); del5395 [del ex9-10]; IVS2 + 1G > A [c.444 + 1G > A]) were detected in 7/280 (2.5%) TC patients vs. 3/424 (0.7%) healthy men and 6/1007 (0.6%) healthy women [OR 4.0 (95% CI 1.5–11), p = 0.009 for pooled control groups]. Somatic CHEK2 loss-of-heterozygosity (LOH) was detected in 4 out of 6 tumors available for analysis; strikingly all these instances of LOH involved inactivation of the wild-type allele. The CHEK2 c.470T > C (p.Ile157Thr) variant was detected in 21/280 (7.5%) affected vs. 22/424 (5.2%) non-affected men [OR 1.5 (95% CI 0.8–2.7), p = 0.3]. Somatic CHEK2 LOH was revealed only in 6 out of 21 tumors obtained from CHEK2 c.470T > C (p.Ile157Thr) carriers, with the C-allele lost in two cases and T-allele deleted in four tumors. The results of comparison of allele frequencies in TC patients versus population controls coupled with the data on CHEK2 LOH status in tumor tissues support the association of CHEK2 pathogenic variants with TC risk.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalFamilial Cancer
Volume20
Issue number1
DOIs
StatePublished - Jan 2021

    Research areas

  • CHEK2 mutation, Loss of heterozygosity, Testicular cancer

    Scopus subject areas

  • Genetics
  • Oncology
  • Genetics(clinical)
  • Cancer Research

ID: 75174833